NCT02523547View on ClinicalTrials.gov

Study to Evaluate the Non-inferiority of Cavir in HBeAg(+)Chronic Hepatitis B Patients Treated With Baraclude

PHASE4UnknownINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

February 28, 2017

Study Completion Date

February 28, 2017

Conditions
Chronic Hepatitis B
Interventions
DRUG

Cavir

0.5mg/day

DRUG

Baraclude

0.5mg/day

Trial Locations (1)

Unknown

RECRUITING

15 Sites, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT02523547 - Study to Evaluate the Non-inferiority of Cavir in HBeAg(+)Chronic Hepatitis B Patients Treated With Baraclude | Biotech Hunter | Biotech Hunter